Abstract

In FY2017, we have identified several potential new agents for the treatment of pediatric-type sarcomas. We have published our findings on PEN-866, a novel HSP90 inhibitor-SN38 drug conjugate, which shows remarkable activity in preclinical models of rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. We have subsequently opened a clinical trial to test this agent in the phase 1 setting and have recently begin to enroll patients. Additionally, we have identified several agents/combinations of agents that are active in Ewing sarcoma and are in the process of further studying their mechanisms preclinically.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011774-01
Application #
9556739
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code